Catálogo de publicaciones - libros

Compartir en
redes sociales


The Physics of Coronary Blood Flow

M. Zamir

Resumen/Descripción – provisto por la editorial

No disponible.

Palabras clave – provistas por la editorial

Biophysics and Biological Physics

Disponibilidad
Institución detectada Año de publicación Navegá Descargá Solicitá
No detectada 2005 SpringerLink

Información

Tipo de recurso:

libros

ISBN impreso

978-0-387-25297-1

ISBN electrónico

978-0-387-26019-8

Editor responsable

Springer Nature

País de edición

Reino Unido

Fecha de publicación

Información sobre derechos de publicación

© Springer Science+Business Media, Inc. 2005

Cobertura temática

Tabla de contenidos

Static Design Issues

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 1-34

Modelling Preliminaries

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 35-77

Basic Lumped Elements

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 79-114

Forced Dynamics of the RLC System

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 115-143

The Analysis of Composite Waveforms

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 145-175

Composite Pressure-Flow Relations

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 177-220

Lumped Models

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 221-254

Elements of Unlumped-Model Analysis

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 255-298

Basic Unlumped Models

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 299-360

Dynamic Pathologies

M. Zamir

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Pp. 361-389